← Back to headlines
These 4 charts show the scale of Novo Nordisk's woes
Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the company now only captures about 40% of the market.
25 Feb, 10:32 — 25 Feb, 10:32
ℹOnly 1 source covers this story
Related Stories
Over 34,000 persons have benefited under 30 ‘Nalam Kaakkum Stalin’ camps organised in Tenkasi district
8m ago
Chandrababu Naidu Reviews Diarrhoea Outbreak in Srikakulam and Milk Contamination in Rajahmundry
10m ago
Serbia Introduces Electronic Health Records Nationwide
12m ago
Albanian NGO Warns of Health Risks for Patients Due to Traffic Blockages
15m ago